Novartis
Novartis becomes global eye health leader as Alcon deal finalised
December 15, 2010Manufacturing and Production, Research and Development, Sales and Marketing Alcon, Lucentis, Novartis, eye care, eye health, ophthalmology
Novartis’ 11-month standoff with Alcon shareholders has ended, allowing it to acquire all the remaining shares in the ophthalmology firm. …
Hormone therapy drugs ‘increase heart disease risk’
December 10, 2010Research and Development AstraZeneca, Hormone therapy, Novartis, Pfizer, aromatase inhibitors, breast cancer, tamoxifen
Three aromatase inhibitors could increase the risk of heart disease in postmenopausal women with breast cancer, according to new data. …
Novartis to cut 1,400 US sales jobs
December 2, 2010Sales and Marketing Novartis, Novartis Pharma North America, Novartis Pharmaceuticals Corporation, job cuts, sales representatives
Novartis has outlined a major restructure of its US field force of sales reps that will see 1,400 positions cut …
Novartis fails to sway NICE with Afinitor deal
November 26, 2010Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis, advanced renal cell carcinoma, everolimus
Novartis has failed to convince NICE that its revised patient access scheme for Afinitor would make the kidney cancer drug …
Bayer’s challenger to Lucentis shows promise
November 22, 2010Research and Development, Sales and Marketing Bayer, Lucentis, Novartis, Regeneron, Roche, VEGF Trap-Eye, age-related macular degeneration, avastin, wet AMD
Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …
Novartis outlines business strategy
November 18, 2010Research and Development, Sales and Marketing Novartis, business development, pharma strategy
Novartis has outlined its long-term strategy for managing a number of key patent expiries. The Swiss-based pharma firm plans to …
Novartis drops late stage lung cancer candidate
November 11, 2010Research and Development ASA404, Antisoma, NSCLC, Novartis, cancer research, lung cancer, non small cell lung cancer, non-small cell lung cancer
Novartis has discontinued phase III trials for its lung cancer candidate ASA404 after it once again failed to meet its …
Novartis signs Middle East vaccine production deal
November 9, 2010Manufacturing and Production Agrippal, Arabio, Novartis, Quinvaxem, meningitis vaccine Menveo, vaccines
Novartis has forged an alliance with a Saudi Arabian manufacturer to help it expand its vaccines business in the Middle …
GCI bags Novartis’ social media director
November 8, 2010Medical Communications GCI Health, Mark Davis, Novartis, appointment, medical communications
Novartis Pharmaceuticals’ former social media director Mark Davis has moved to GCI Health. He has been appointed to lead the …
FDA approves Novartis’ Afinitor
November 1, 2010Sales and Marketing Afinitor, Novartis, subependymal giant cell astrocytomas, tuberous sclerosis
Novartis’ drug Afinitor has been approved by US authorities as a first line treatment for patients with benign brain tumours …
Novartis’ Lucentis recommended for wider EU licence
October 25, 2010Sales and Marketing CHMP, Genentech, Lucentis, Novartis, diabetic macular edema, ranibizumab
Novartis’ Lucentis has been recommended for approval in Europe to treat people suffering from vison loss due to diabetes. The …
Two thirds of pharma companies face ‘strategic crisis’
October 25, 2010Research and Development, Sales and Marketing Novartis, Pfizer, Roland Berger, generics, pharma research, pharma sales
The pharma industry is moving away from traditional in-house innovation and toward a more diversified business model, but will encounter …
Novartis posts strong Q3 results
October 21, 2010Sales and Marketing 2010 financials, Novartis, Novartis quarterly results, Q3, pharma sales
Novartis has posted double digit growth for the third quarter following a strong showing by a number of recently launched …
Cutting-edge cancer treatments showcased at ESMO
October 18, 2010Research and Development AstraZeneca, Boehringer, Cancer, Cancer Conference, Johnson & Johnson, Novartis, personalised medicine
The search for a ‘silver bullet’ against cancer has failed, for now, with the battle against the disease turning instead …
Trial shows long-term benefits of Novartis’ Aclasta
October 18, 2010Research and Development, Sales and Marketing Novartis, aclasta, osteoporosis
Novartis has published new data at the annual meeting of the American Society for Bone and Mineral Research in Toronto …
Latest content
FibroFind appoints Lee Borthwick as CEO
